(atdn) insulin-like growth factor

AIDS Treatment Data Network (ATDN) Insulin-like Growth Factor
December 1, 1994

Treatment Review #15; December 1994 Insulin-like growth factor (IGF-1) is produced by the liver in response to human growth hormone. Many of growth hormone's effects may be the result of IGF-1. Human growth hormone is described in the article on serostim on page 3. A trial comparing growth hormone and IGF-1 for the treatment of children and adolescents with HIV infection is being conducted at the National Cancer Institute. To participate in this trial, you must be 6 to 18 years old with a failure to grow or less than normal weight or height. Participants will be divided into two groups. One group will be given IGF-1 twice a day. The second group will be given human growth hormone once a day. Both treatments are given by shot. Participants being given IGF-1 will have to be in the hospital for five days. Total time on study is 6 months.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 TB, HIV and malaria vaccine research gets major boost Measuring hidden HIV Investigators at National Autonomous University Detail Findings in AIDS Education and Prevention Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases Adopted Russian orphan triumphs over challenges 26th Annual Minnesota AIDS Walk - Sunday, May 19, Minnehaha Park 'Gap' for HIV vaccine efforts after latest setback AIDS science at 30: 'Cure' now part of lexicon ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak MALAWI: Marriage Is a Risk Factor for HIV Infection in Malawi NEW YORK: 3 File Suit on Hepatitis Tied to Insulin Pen Reuse in Olean Former patients sue NY hospital over insulin pens Community Kitchen marks 3 decades of growth Drugmakers eye Africa's middle classes as next growth market GSK promises growth this year after 2012 shortfall GLOBAL: Co-infection with Hepatitis B or C Is a Risk Factor for Reduced Bone Mineral Density Among Women with HIV Co-infection with hepatitis B or C is a risk factor for reduced bone mineral density among women with HIV NEW YORK: Second NY Hospital Warns Patients About Potential HIV, Hepatitis Exposure From Insulin Pens 2nd NY hospital warns of insulin pen infection
Copyright © 1994 -AIDS Treatment Data Network, Publisher. All rights reserved to AIDS Treatment Data Network. Reproduction of this article (other than one copy for personal reference) must be cleared through the AIDS Treatment Data Network. Email AIDS Treatment Data Network Information in this article was accurate in December 1, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.